Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$10.98
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.98
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume146.24K
Average Volume (3M)3.41M
Market Cap
$2.32B
Enterprise Value$1.45B
Total Cash (Recent Filing)$347.82M
Total Debt (Recent Filing)$286.18M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 03, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding150,560,990
10 Day Avg. Volume2,228,550
30 Day Avg. Volume3,412,790
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-704.59
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$17.70Price Target Upside61.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal RISE3 Enrollment (opakalim)Completing enrollment in the pivotal RISE3 program and targeting top-line readouts in 2H 2026 materially de-risks Biohaven’s epilepsy franchise. A successful pivotal readout can unlock regulatory progress or partnering, shifting the company toward commercialization and reducing binary early-stage exposure.
BHV-1300 Phase 3 — First MoDE DegraderInitiation of a pivotal Phase 3 for BHV-1300 positions Biohaven with a potential first-in-class therapy in a market lacking new treatments for decades. This novel MoDE mechanism creates a structural opportunity for durable clinical differentiation, commercial leadership, and strategic partnerships if trials succeed.
Scientific Leadership & Collaboration FocusStrengthening discovery leadership while retaining the outgoing CSO in an innovation role concentrates senior expertise on both internal R&D and external partnerships. This governance change is likely to boost discovery productivity, streamline collaborations, and preserve institutional knowledge while cutting fixed costs.
Bears Say
No Revenue; Large Recurring LossesBiohaven reports zero product revenue and persistent, large net losses (roughly -$739M in 2025; -$648M TTM). Without commercial revenue, the company must rely on successful clinical outcomes and external financing; sustained losses increase dilution risk and make long-term viability contingent on trial successes.
Severe Negative Operating And Free Cash FlowDeeply negative operating cash flow (~ -$609M in 2025; -$594M TTM) and negative free cash flow indicate ongoing high burn. This persistent outflow necessitates recurrent capital raises, constrains resource allocation, and elevates execution and dilution risk over the coming months absent material clinical or financing events.
Sharp Rise In Debt And Compressed EquityLeverage increased sharply as debt jumped to ~$279M while equity collapsed to ~$52M, pushing debt/equity to multi‑times. The compressed equity base and higher leverage reduce financial flexibility, increase refinancing and covenant risk, and make future capital structure choices more constrained absent positive trial outcomes.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.32B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 13 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 04, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.831 by -$0.049.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.75.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,560,990 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.831. Following the earnings report the stock price went down -4.241%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.70 (61.20% Upside)
$17.70 (61.20% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
BHVN Stock 12 Month Forecast
Average Price Target
$17.70
▲(61.20% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
11.98% Mutual Funds
1.73% Other Institutional Investors
66.94% Public Companies and
Individual Investors